Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Acquir Immune Defic Syndr ; 87(2): 818-825, 2021 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-33512849

RESUMO

BACKGROUND: Initiating pre-exposure or post-exposure prophylaxis (PrEP/PEP) in the setting of undiagnosed acute HIV (AHI) could cause antiretroviral resistance. We sought to characterize clinical outcomes and drug resistance mutations among individuals prescribed PrEP/PEP with undiagnosed AHI at a San Francisco sexually transmitted disease clinic. SETTING: In our PrEP/PEP program, patients are tested for HIV using a point-of-care antibody test. If negative, patients are started on prophylaxis and screened for AHI using pooled HIV RNA (5-10 days turn-around). We used 2-drug PEP until 05/2016. METHODS: We identified patients who had as-yet-undiagnosed AHI on the day of PrEP/PEP start between 2011 and 2018, then used our clinical record and surveillance data to describe HIV resistance and clinical outcomes. RESULTS: Of 1758 PrEP and 2242 PEP starts, there were 7 AHI cases among PrEP users (0.40%) and 6 among PEP users (0.30%). Median times for linkage to HIV care, initiation of HIV treatment, and viral suppression were 7, 12, and 43 days. On initiation of HIV care, 3 patients (23%) were found to have an M184 mutation 7-12 days after starting PrEP/PEP. All 3 had genotyping performed on stored serum available from the date of PrEP/PEP start, each of which demonstrated wild-type virus. All 3 patients achieved durable viral suppression. CONCLUSIONS: Although rare (occurring <0.5% of the time), AHI in the setting of PrEP/2-drug PEP can result in an M184 within days. Even with M184, persons with AHI achieve viral suppression when rapidly linked to care and initiated on antiretroviral therapy. Providers should consider AHI screening when starting PrEP/PEP.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Farmacorresistência Viral/genética , Infecções por HIV/prevenção & controle , HIV-1/genética , Profilaxia Pós-Exposição/métodos , Profilaxia Pré-Exposição/métodos , Adulto , Emtricitabina/uso terapêutico , Feminino , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , Homossexualidade Masculina , Humanos , Masculino , Pessoa de Meia-Idade , Testes Imediatos , Estudos Retrospectivos , São Francisco , Tenofovir/uso terapêutico , Resultado do Tratamento , Doenças não Diagnosticadas/diagnóstico , Doenças não Diagnosticadas/virologia
2.
PLoS One ; 15(9): e0239647, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32970745

RESUMO

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most significant global health crisis of the 21st century. The aim of this study was to develop a model to simulate the effect of undocumented infections, seasonal infectivity, immunity, and non-pharmaceutical interventions (NPIs) on the transmission, morbidity, and mortality of SARS-CoV-2 in New York State (NYS) based on data collected between March 4 and April 28, 2020. Simulations predict that undocumented infections significantly contribute to infectivity, NPIs are effective in reducing morbidity and mortality, and relaxation >50% of NPIs from initial lock-down levels may result in tens-of-thousands more deaths. Endemic infection is likely to occur in the absence of sustained immunity. As a result, until an effective vaccine or other effective pharmaceutical intervention is developed, the risks of significantly reducing NPIs should be carefully considered. This study employs modelling to simulate fundamental characteristics of SARS-CoV-2 transmission, which can help policymakers navigate combating this virus in the coming years.


Assuntos
Infecções por Coronavirus/mortalidade , Pneumonia Viral/mortalidade , Doenças não Diagnosticadas/epidemiologia , Betacoronavirus , COVID-19 , Simulação por Computador , Infecções por Coronavirus/transmissão , Previsões , Humanos , Imunidade , Modelos Teóricos , New York/epidemiologia , Pandemias , Pneumonia Viral/transmissão , SARS-CoV-2 , Estações do Ano , Doenças não Diagnosticadas/virologia
3.
J Korean Med Sci ; 35(29): e269, 2020 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-32715672

RESUMO

BACKGROUND: Seroprevalence studies of coronavirus disease 2019 (COVID-19) from many countries have shown that the number of undiagnosed missing cases is much larger than that of confirmed cases, irrespective of seroprevalence levels. Considering the strategy of Korea entailing massive testing and contact tracing from the beginning of epidemic, the number of undiagnosed missing cases in Korea may be negligible. This study was conducted to estimate the seroprevalence of COVID-19 among individuals who were never diagnosed with COVID-19 in Daegu, the epicenter of COVID-19 epidemic in Korea. METHODS: Serologic testing for immunoglobulin G antibody based on immunochromatographic assay was conducted in 103 patients and 95 guardians aged 18 to 82 years without any history of COVID-19 diagnosis, who visited outpatient clinics of a single university-affiliated hospital from May 25 to June 5, 2020. RESULTS: The estimated seroprevalence was 7.6% (95% confidence interval, 4.3%-12.2%) with 15 positive cases. Among them, only one had a polymerase chain reaction (PCR)-confirmed case among their close contacts and 13 did not experience COVID-19-related symptoms. Seroprevalence was similar between patients and guardians. Based on this figure, the number of undiagnosed missing cases in Daegu was estimated to be a dozen times more than the number of confirmed cases based on PCR testing. CONCLUSION: Despite the limitation of a small and unrepresentative sample, this is the first study on seroprevalence of COVID-19 in Korea. Our study suggested that the number of undiagnosed missing cases was substantial even with the stringent strategy adopted in Korea, similar to that of other countries.


Assuntos
Anticorpos Antivirais/sangue , Infecções por Coronavirus/epidemiologia , Imunoglobulina G/sangue , Pneumonia Viral/epidemiologia , Estudos Soroepidemiológicos , Doenças não Diagnosticadas/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Instituições de Assistência Ambulatorial , Betacoronavirus/imunologia , COVID-19 , Busca de Comunicante , Infecções por Coronavirus/sangue , Infecções por Coronavirus/diagnóstico , Feminino , Humanos , Imunoglobulina G/imunologia , Masculino , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/sangue , Pneumonia Viral/diagnóstico , Reação em Cadeia da Polimerase , República da Coreia/epidemiologia , SARS-CoV-2 , Testes Sorológicos , Inquéritos e Questionários , Doenças não Diagnosticadas/virologia , Adulto Jovem
4.
Sci Rep ; 10(1): 3180, 2020 02 21.
Artigo em Inglês | MEDLINE | ID: mdl-32081931

RESUMO

Fifty patients with unexplained fever and poor outcomes presented at Irrua Specialist Teaching Hospital (ISTH) in Edo State, Nigeria, an area endemic for Lassa fever, between September 2018 - January 2019. After ruling out Lassa fever, plasma samples from these epidemiologically-linked cases were sent to the African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria, where we carried out metagenomic sequencing which implicated yellow fever virus (YFV) as the etiology of this outbreak. Twenty-nine of the 50 samples were confirmed positive for YFV by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), 14 of which resulted in genome assembly. Maximum likelihood phylogenetic analysis revealed that these YFV sequences formed a tightly clustered clade more closely related to sequences from Senegal than sequences from earlier Nigerian isolates, suggesting that the YFV clade responsible for this outbreak in Edo State does not descend directly from the Nigerian YFV outbreaks of the last century, but instead reflects a broader diversity and dynamics of YFV in West Africa. Here we demonstrate the power of metagenomic sequencing for identifying ongoing outbreaks and their etiologies and informing real-time public health responses, resulting in accurate and prompt disease management and control.


Assuntos
Sistemas Computacionais , Surtos de Doenças , Metagenoma , Doenças não Diagnosticadas/epidemiologia , Doenças não Diagnosticadas/genética , Febre Amarela/epidemiologia , Febre Amarela/genética , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Funções Verossimilhança , Masculino , Pessoa de Meia-Idade , Nigéria/epidemiologia , Filogenia , Doenças não Diagnosticadas/virologia , Febre Amarela/virologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...